Enhanced Reprogramming Efficiency and Kinetics of Induced Pluripotent Stem Cells Derived from Human Duchenne Muscular Dystrophy

This study laid the preliminary findings that can be further extended to combine the ex-vivo gene and autologous cell therapy to exploit the therapeutic way to treat DMD that avoid immune rejection with sufficient engraftment ability 40,4. Also, the immaculate expertise in patient-derived iPSCs can accelerate the possibility of personalized medicine in the clinical arena.
Competing Interests
The authors indicate no potential conflicts of interest.
Author Information
Corresponding Author: Sujata Mohanty, Ph.D.
Complete Mailing Address: Stem Cell Facility, 1st Floor ORBO Complex,
All India Institute of Medical Sciences,
Ansari Nagar, New Delhi-110 029
Telephone and Fax Numbers: [phone] (Telephone)
[phone] (Fax)
Email Id: [e-mail]
Pooja Teotia: [e-mail]
Sujata Mohanty: [e-mail]
Madhulika Kabra: [e-mail]
Sheffali Gulati: [e-mail]
Balram Airan: [e-mail]
Short Title: i-PSCs for human Duchenne muscular dystrophy.

Source: PLOS Currents Muscular Dystrophy - September 3, 2015 Category: Neurology Authors: Pooja Teotia Source Type: research